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Abstract
 
Although all three Vav family members are expressed in T lymphocytes, the role that Vav3
plays in T cell activation is poorly defined. Here we show that, like Vav1, Vav3 undergoes
rapid tyrosine phosphorylation after T cell receptor (TCR) cross-linkage and interacts with the
adaptor molecules SLP76 and 3BP2 in a SH2-dependent manner. However, depletion of Vav1
but not Vav3 protein by RNA interference affects TCR-mediated IL-2 promoter activity. In
contrast, Vav3 function is specifically required for coupling TCR stimulation to serum response
element–mediated gene transcription. These data indicate that, although both Vav proteins are
biochemically coupled to the TCR, they regulate distinct molecular pathways leading to defined
gene transcriptional events.
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Introduction
 
The engagement of the TCR with MHC–peptide complexes
on antigen-presenting cells leads to the activation of proximal
protein tyrosine kinases, resulting in the tyrosine phosphor-
ylation of multiple membrane-bound and cytosolic proteins
(1). One signaling protein that undergoes phosphorylation
within seconds of TCR cross-linkage is the Vav1 proto-
oncogene (2). Vav1 is a member of the Dbl superfamily of
Rho/Rac guanine nucleotide exchange factors that is ex-
pressed primarily in cells of the hematopoietic lineage (3).
The importance of Vav1 in the regulation of T cell activation
is highlighted by defects in both thymocyte development
and peripheral T cell activation in 
 
vav1
 
 
 
/
 
 
 
 mice (4). Moreover,
studies in a Vav1-deficient Jurkat T cell line, J.Vav1, dem-
onstrate that Vav1 couples TCR/CD28 signals to pathways
leading to transcriptional regulation of the IL-2 promoter
(5). Two additional members of the Vav family of guanine
nucleotide exchange factor (Vav2 and Vav3) have been
identified that are also expressed in hematopoietic cell lineages
and undergo TCR-induced tyrosine phosphorylation (6–9).
However, whether human Vav2 or Vav3 act as functionally
redundant or distinct signaling proteins during T cell acti-
vation is not known.
Although previous studies have demonstrated that murine
Vav3 undergoes TCR-induced tyrosine phosphorylation in
the Jurkat T cell line when ectopically expressed (8), the
role of human Vav3 in the regulation of T cell activation is
poorly understood. To begin to elucidate the role of Vav3
in signaling downstream of the TCR, we have studied Vav3
in the Jurkat T cell line using biochemical approaches and
small-interfering RNA-mediated gene silencing. The results
of these studies indicate that Vav1 and Vav3 couple TCR-
induced signals to distinct molecular pathways leading to
IL-2 promoter activation and serum response element
(SRE)–dependent gene transcription, respectively.
 
Materials and Methods
 
Reagents and Plasmids.
 
All reagents are from Sigma-Aldrich
unless otherwise specified. The antisera against Vav, SLP76, and
3BP2 have been described previously (5, 9–11). The anti-CD28
mAb was purchased from BD Biosciences, and the antiphosphoty-
rosine mAb (4G10) was purchased from Upstate Biotechnology.
The expression plasmids for Vav3, SLP76, and 3BP2 and the
luciferase reporter constructs have been described previously (5,
10, 11). The SRE- and ternary complex factor (TCF)–luciferase
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reporter plasmids were provided by Dr. Ralf Janknecht (Mayo
Clinic). The serum response factor (SRF)–luciferase reporter plas-
mid was obtained from Stratagene. The RNA targeting vector
was generated as previously described (12). The 19-nucleotide se-
quence used to target Vav1 and Vav3 mRNA is TCTCTAC-
CAGGTCTTCATC and GCTTTGTCTAACATAAGAC, re-
spectively. Mutant targeting constructs were also generated to
Vav1 (TgTCTAaCAGGTCTcCATC) and Vav3 (GCTaTGTc-
TAtCATAAGAC) as controls.
 
Cell Culture, Transfection, and Stimulation.
 
All cells were
grown and transfected as described previously (5). For luciferase
reporter assays, cells (10
 
6
 
 cells) were distributed in triplicate in 24-
well plates and stimulated as indicated. Samples were harvested
and prepared for luciferase assays according to the protocol sug-
gested by the manufacturer (Promega). All reporter assays were
cotransfected with a pRL-TK reporter plasmid (Promega) to
control for intersample variations in transfection efficiency. In the
latter case, firefly and pRL-TK–derived 
 
Renilla
 
 luciferase activi-
ties were measured in each sample with a Dual Luciferase Assay
kit (Promega).
 
Immunoblot Analysis.
 
Jurkat T cells were used directly or
were electroporated with the indicated expression constructs.
Following electroporation, the cells were lysed as described pre-
viously (5). Endogenous or FLAG-tagged proteins were immu-
noprecipitated from the lysate, washed, eluted in 40 
 
 
 
l of SDS
sample buffer, resolved by SDS-PAGE, and transferred to Immo-
bilon-P membranes (Millipore). FLAG-tagged and tyrosine-phos-
phorylated proteins were detected using anti-pTyr and anti-FLAG
mAb followed by goat anti–mouse IgG coupled to horseradish
peroxidase (Santa Cruz Biotechnology, Inc.) and the SuperSignal
detection system was from Pierce Chemical Co. Endogenous
Vav, SLP-76, and GST-bound proteins were detected using spe-
cific polyclonal rabbit antisera followed by protein A linked to
horseradish peroxidase (Amersham Biosciences) and SuperSignal.
In some instances, GST fusion proteins containing the SH2 do-
main of either, Vav1, Vav2, or Vav3 were used to immunopre-
cipitate interacting proteins from TCR-stimulated Jurkat T cells
as described previously (13).
 
Results and Discussion
 
Vav3 Links to the TCR and Interacts with SLP-76.
 
To
determine the role of Vav3 in TCR signaling, we initially
compared the kinetics of tyrosine phosphorylation of the
three distinct Vav isoforms after TCR cross-linkage in the
Jurkat T cell line. Although basal levels of Vav1 tyrosine
phosphorylation are apparent, there is little or no detectable
basal tyrosine phosphorylation of Vav2 or Vav3 (Fig. 1 A).
However, upon TCR cross-linking all three Vav family
members undergo rapid tyrosine phosphorylation with
peak phosphorylation attained at 1 min poststimulation and
a gradual decline in phosphotyrosine content observed at
later time points. Similar results were observed when Vav1
and Vav3 tyrosine phosphorylation was measured after
TCR cross-linkage in a CD4
 
 
 
 human T cell clone (Fig. 1
B). Thus, all three Vav proteins couple to the TCR and
show similar kinetics of tyrosine phosphorylation.
To determine if the SH2 domain of Vav3 is required for
its tyrosine phosphorylation downstream of the TCR, we
transfected Jurkat T cells with either a WT or SH2 domain
mutant of Vav3 and analyzed TCR-induced tyrosine phos-
phorylation of the two proteins. As shown in Fig. 2 A, the
mutant SH2 domain–containing Vav3 protein fails to un-
dergo TCR-mediated tyrosine phosphorylation. This was
not the result of different levels of protein expression since
both Vav3 proteins were equivalently expressed.
It is of interest that this mutant protein fails to interact
with a tyrosine-phosphorylated protein with apparent mo-
lecular weight of 76 kD (Fig. 2 B, asterisk). Since Vav1 and
Vav2 have been observed to interact with SLP76 (14, 15),
we questioned whether Vav3 also interacts with SLP76
downstream of the TCR. Anti-Vav3 or anti-SLP76 anti-
bodies were incubated with detergent extracts from Jurkat
T cells that were left unstimulated or stimulated by anti-
CD3 or treatment with pervanadate. As shown in Fig. 2 B,
immunoprecipitation of Vav3 after TCR cross-linkage re-
sults in an inducible association with SLP76. In addition,
Vav3 was also observed in SLP76 immunoprecipitates (Fig.
2 B, bottom), indicating that these two proteins become
physically associated after TCR cross-linking. Given that
the Vav1 SH2 domain is important for linking Vav1 to the
TCR and SLP76 (14), we determined if the interaction of
Vav3 with SLP76 was mediated through the Vav3 SH2 do-
main using GST fusion proteins. Consistent with previous
results, GST fusion proteins containing the Vav1 and Vav2
SH2 domains captured SLP76 in extracts from anti-CD3–
stimulated T cells (Fig. 2 C). Similarly, the Vav3 SH2 do-
main fusion protein interacted with SLP76 after TCR
cross-linking (Fig. 2 C), indicating that SLP76 is a common
target for the SH2 domain of all three Vav isoforms. Note
that some SLP76 was pulled down in the absence of stimu-
lation but was not detected on the anti-pTyr blot, most
likely due to the level of tyrosine phosphorylation. There-
Figure 1. Vav proteins couple to the T cell receptor. (A) Jurkat T cells
or (B) a CD4  T cell clone were treated as indicated. The different Vav
isoforms were specifically immunoprecipitated (Vav1, top; Vav2, middle;
and Vav3, bottom) using Vav-specific polyclonal rabbit antisera. The
immunoprecipitates were resolved by SDS-PAGE, transferred to a nylon
membrane, and probed with anti-pTyr (top panel in each set) or anti-Vav
(bottom panel in each set). 
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fore, like Vav1 and Vav2, Vav3 has the potential to interact
with SLP76. It is likely, that the SH2 domain of all three
Vav proteins interact with an overlapping set of tyrosine
molecules that conform to the (p)YXEP motif (where X is
either M, L, or E) (3).
Lastly, in order to demonstrate that this interaction is
direct we performed a “Far-Western” blot using the GST–
Vav3–SH2 fusion protein as a probe on SLP76 immuno-
precipitates from TCR-stimulated cells that had been trans-
fected with either WT SLP76 or a mutant SLP76 in which
all three tyrosines within the acidic region were mutated to
phenylalanine (3YF). As shown in Fig. 2 D, the Vav3 SH2
domain GST fusion protein specifically interacted with the
WT SLP76 protein. However, consistent with the mecha-
nism of the Vav1-SLP76 interaction, Vav3 did not interact
with the 3YF mutant protein. Thus, similar to what has
been described for Vav1, the interaction of Vav3 with
SLP76 is mediated through tyrosine-phosphorylated resi-
dues within the SLP76 acidic region (Y112, Y128, and
Y145) (16, 17). In addition to SLP76, we also found that
the SH2 domain of Vav3 directly interacts with the adaptor
protein 3BP2, a protein involved in TCR-mediated nu-
clear factor of activated T cells (NFAT)/AP-1 activity and
NK cell-mediated natural cytotoxicity (11, 18). Consistent
with our previous observations regarding the interaction of
Vav1 and Vav2 with 3BP2 (11), the Vav3–3BP2 interac-
tion primarily occurs through Y183, since we observed a
significant reduction in binding of the Vav3-SH2 domain
when this residue was mutated to phenylalanine (Fig. 2 D).
The significance of Y183 in 3BP2 is highlighted by the in-
ability of the Y183F mutant protein to augment cell-medi-
ated killing when expressed in NK cells (11). Whether
Vav3 couples to 3BP2 in NK cells and regulates NK cell
killing remains to be established. Together, these data show
that the SH2 domain of Vav3, like that of Vav1 and Vav2,
can couple this family of signaling mediators with an over-
lapping set of adaptor proteins downstream of the TCR.
 
Suppression of Vav3 Has No Effect on TCR-induced IL-2
Promoter Activity.
 
The above results suggest that Vav1
and Vav3 couple to overlapping pathways in T cells after
Figure 2. Vav3 interacts with SLP76 and 3BP2. (A) Jurkat T cells were transfected with the indicated expression vectors. Cells were stimulated as
indicated, cell lysates were prepared, and FLAG-tagged protein was immunoprecipitated. Immunoprecipitates were analyzed as described above and
probed for anti-pTyr (top) and anti-FLAG (bottom). The asterisk denotes an interacting protein of  76 kD. The arrow denotes a nonspecific band.
(B) Jurkat T cells were treated as indicated, and cell lysates were prepared and subject to immunoprecipitation with NRS, anti-Vav3, or anti-SLP76
polyclonal rabbit antisera. Proteins were detected using anti-pTyr (top), anti-SLP76 (middle), or anti-Vav3 (bottom). In the anti-pTyr blot, the asterisk
denotes SLP76, and the arrow identifies Vav3. (C) GST or GST fusion proteins containing the Vav1, Vav2, or Vav3 SH2 domains were used to immu-
noprecipitate interacting proteins from unstimulated ( ) or CD3-stimulated ( ) Jurkat T cells. Interacting proteins were analyzed using anti-pTyr (top)
or anti-SLP76 (bottom). The arrow denotes the SLP76 band. (D) Jurkat T cells were transfected with the indicated expression vectors. Cells were
treated as in B, and the membrane was subsequently probed with the GST–Vav3–SH2 (1  g/ml) and detected with anti-GST (top), anti-pTyr (middle),
and anti-FLAG (bottom). 
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TCR cross-linkage. However, it is clear that Vav3 is not
functionally redundant with Vav1, since T cell activation
pathways are severely compromised in vav1
 
 
 
/
 
 
 
 murine T
cells and IL-2 promoter activity is severely impaired in
J.Vav1 cells after activation (5). Thus, it is possible that
Vav3 does not normally regulate the molecular pathways
that activate the IL-2 promoter after TCR ligation. To
test this, we generated short-hairpin RNA interference
vectors that specifically target either Vav1 (shVav1) or
Vav3 (shVav3). As shown in Fig. 3 A, when Vav1 or
Vav3-targeting vectors are transiently transfected into Jur-
kat T cells we observe a significant loss of Vav1 and Vav3
protein up to 96 h posttransfection.
To investigate if depletion of Vav3 has a similar effect on
IL-2 promoter activity to that of Vav1, we cotransfected
Jurkat T cells with the full-length IL-2 promoter reporter
construct and the indicated RNA targeting vectors and
measured luciferase activity after CD3 or CD3/CD28
cross-linking. Consistent with data from the J.Vav1 cell
line, depletion of Vav1 severely compromises CD3 and
CD3/CD28-mediated IL-2 promoter activity when com-
pared with the control transfected population (Fig. 3 A)
(5). In stark contrast, Jurkat T cells in which Vav3 protein
had been depleted by RNA interference showed no de-
monstrable defect in either CD3 or CD3/CD28-mediated
IL-2 promoter activity (Fig. 3 A). Moreover, whereas de-
pletion of Vav1 impacted on NFAT/AP-1–, NF-
 
 
 
B–, and
AP-1–mediated gene transcription, Vav3 depletion had no
effect (Fig. 3, C and D; not depicted). Previous data suggest
that when overexpressed Vav3 is capable of augmenting
NF-
 
 
 
B activity downstream of the TCR in Jurkat T cells
(8) and functionally substituting for Vav1 in the J.Vav1 cell
line (5). Yet, the results presented here suggest that Vav3
does not share with Vav1 the ability to transduce TCR-ini-
tiated signals leading to the activation of transcription fac-
tors that are required for IL-2 gene transcription. More-
over, these results suggest that caution be taken when
analyzing data using overexpression, since such experimen-
tal systems may not always fairly recapitulate the normal
role of a signaling protein. However, using the J.Vav1 cell
line we have been able to further diminish TCR-induced
IL-2p activity after the suppression of Vav3 by RNA inter-
ference (unpublished data), indicating that Vav1 is the
dominant Vav family member in this pathway but that
Vav3 can couple, although weakly, some TCR-induced
signals leading to IL-2 promoter activity. Consistent with
this notion, a recent study of Vav-deficient animals has
demonstrated that the 
 
vav1/3
 
 
 
/
 
 
 
 T cell phenotype is worse
than 
 
vav1
 
 
 
/
 
 
 
 T cells (19).
 
Vav3 Couples TCR-induced Signaling Pathways to SRE-
mediated Gene Transcription.
 
Vav proteins have been sug-
gested to activate an overlapping set of Rho family GTP-
binding proteins (20). This family of GTP-binding proteins
regulate downstream effector pathways that modulate SRE-
dependent gene transcription (21, 22). Efficient transactiva-
tion of the SRE requires the binding of SRF and the ter-
nary TCF complex (23). It is of interest that the activation
of both transcription factors requires phosphorylation events
Figure 3. Vav1 but not Vav3 links TCR-induced signals to IL-2 promoter activity. (A) Jurkat T cells were transfected with either a control suppression
vector (pFRT) or a Vav1 (shVav1) or Vav3 (shVav3) RNA targeting vector. Cell lysates were prepared at the indicated time intervals posttransfection,
and 100  g of total protein was immunoblotted with anti-Vav1 (top) and anti-Vav3 (bottom) or anti-ZAP70 as a loading control. (B–D) Jurkat T cells
were transfected with luciferase reporter containing the IL-2p (B), NFAT/AP-1 (C), or NF- B (D), and the indicated RNA suppression constructs. 36 h
posttransfection, cells were treated, and luciferase activity was measured as indicated in Materials and Methods. Bars represent the mean   SD from trip-
licate samples. Western blotting of 100  g of protein prepared from the indicated transfected cell population was performed to demonstrate the depletion of
the indicated Vav isoform. 
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mediated in part by members of the MAPK family (24). In-
deed, T cells from 
 
vav1
 
 
 
/
 
 
 
 mice fail to activate ERK in re-
sponse to low levels of TCR stimulation (25). Moreover,
previous studies in Jurkat have shown that SRE-dependent
transcription after TCR cross-linking is enhanced by the
overexpression of WT but not dominant-negative forms of
murine Vav1 and murine Vav2 (15, 26). To more directly
assess the role of Vav1 in controlling SRE-dependent gene
transcription downstream of the TCR, we initially assessed
SRE-dependent gene transcription in the J.Vav1 cell line.
As shown in Fig. 4 A, although IL-2 promoter activity in-
duced by CD3 or CD3/CD28 ligation is severely compro-
mised in the J.Vav1 cell line (Fig. 4 A, compare Jurkat to
J.Vav1), we observed no defect in either basal level or
TCR-induced SRE-mediated gene transcription (Fig. 4 B,
compare Jurkat to J.Vav1). However, it remained possible
that the J.Vav1 clone retained TCR-induced SRE-medi-
ated gene transcription as a consequence of selection during
the generation of this cell line. To determine if this was the
case, we analyzed SRE-mediated gene transcription in Jur-
kat T cells in which Vav1 was depleted by RNA interfer-
ence. Consistent with the J.Vav1 cells, depletion of Vav1 by
RNA interference in the Jurkat T cell line had minimal to
no effect on TCR-induced SRE-mediated gene transcrip-
tion (Fig. 4 C). These data indicate that caution must be
taken when overexpressing dominant-negative forms of
Vav proteins as they have the potential to “poison” normal
signaling complexes and nonspecifically block signaling
pathways in which they are not a normal component.
To investigate the potential role of Vav3 in SRE-medi-
ated gene transcription, we depleted Vav3 by RNA inter-
ference and measured SRE-luciferase activity. As shown in
Fig. 4 C, RNA interference of Vav3 severely compromises
basal and TCR-induced SRE-dependent gene transcrip-
tion (Fig. 4 C). To further delineate the mechanism by
which Vav3 suppression was affecting SRE-mediated gene
transcription, we assessed the ability of control-transfected
or Vav3-suppressed Jurkat T cells to regulate either
TCF-dependent or SRF-dependent gene transcription. As
shown in Fig. 4 D, depletion of Vav3 protein had no effect
on the TCF reporter but did diminish the basal and TCR-
induced activation of the SRF-specific promoter. The data
presented in Fig. 4, B and C, would suggest that Vav1 is
not necessary to couple TCR-initiated signaling pathways
to the regulation of SRE-mediated gene transcription,
whereas Vav3 is centrally involved in regulating the SRF
transcription factor after TCR cross-linkage. In fact, it has
been shown recently that SRF-dependent gene transcrip-
tion in B cells is JNK independent but ERK dependent
(27). Although our data clearly link Vav3-mediated signal-
ing events to SRF activity, we have not observed any
defect in ERK activation after TCR cross-linking of Vav3-
depleted Jurkat T cells (unpublished data). However, it re-
mains possible that Vav3 is controlling a signaling pathway
downstream of the TCR that regulates SRF activity in a
MAPK-independent manner. Thus, it will be important to
determine which pathway leading to SRF activation is im-
paired in Vav3-depleted Jurkat T cells.
In conclusion, we have identified Vav1 and Vav3 as pos-
itive regulators of distinct TCR-induced transcriptional
events leading to IL-2 promoter activity and SRE-depen-
dent gene transcription, respectively. It will be important
to determine the pathways controlled by Vav3 leading to
SRE-mediated gene transcription and to determine if the
pathways activated by Vav3 are in fact distinct from those
activated by Vav1. Moreover, our data clearly indicate that,
although overexpression studies can give initial insights
into protein function, acute gene silencing with small-
Figure 4. Vav3 couples TCR-initiated
signaling to the regulation of SRE-mediated
gene transcription. (A) Jurkat and J.Vav1 T
cells were transfected with luciferase reporter
containing the IL-2 promoter, stimulated,
and analyzed as indicated in Fig. 3. (B) Jurkat
and J.Vav1 T cells were transfected with
luciferase reporter containing the c-fos SRE
stimulated and analyzed as indicated in Fig. 3.
(C and D) Jurkat were transfected with
luciferase reporter containing the SRE (C),
TCF, or SRF (D) and the indicated RNA
suppression constructs, stimulated, and lu-
ciferase activity was measured as described
in Fig. 3. Bars represent the mean   SD
from triplicate samples. Western blotting of
protein lysates is as described in Fig. 3. 
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interfering RNA represents a more definitive epigenetic
strategy for the functional characterization of TCR-linked
signaling proteins in human T cell lines.
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